Athenex, Inc. (NASDAQ:ATNX) has received an average broker rating score of 2.00 (Buy) from the three brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. Athenex’s rating score has declined by 100% from three months ago as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a twelve-month consensus price objective of $25.73 for the company, according to Zacks. Zacks has also assigned Athenex an industry rank of 110 out of 265 based on the ratings given to related companies.
A number of equities analysts recently issued reports on ATNX shares. Royal Bank Of Canada started coverage on shares of Athenex in a research report on Thursday, September 14th. They set an “outperform” rating and a $35.00 target price on the stock. Laidlaw assumed coverage on shares of Athenex in a report on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price target on the stock. Credit Suisse Group assumed coverage on shares of Athenex in a report on Monday, September 18th. They issued an “outperform” rating and a $25.00 price target on the stock. Finally, J P Morgan Chase & Co assumed coverage on shares of Athenex in a report on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 price target on the stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2017/12/08/zacks-analysts-set-25-73-price-target-for-athenex-inc-atnx.html.
Institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System bought a new stake in shares of Athenex in the 3rd quarter worth about $198,000. Bank of New York Mellon Corp acquired a new position in Athenex during the 2nd quarter worth about $240,000. Tudor Investment Corp ET AL acquired a new position in Athenex during the 2nd quarter worth about $320,000. Schwab Charles Investment Management Inc. acquired a new position in Athenex during the 3rd quarter worth about $524,000. Finally, Goldman Sachs Group Inc. acquired a new position in Athenex during the 2nd quarter worth about $601,000. 1.28% of the stock is currently owned by institutional investors and hedge funds.
Shares of Athenex (NASDAQ ATNX) traded up $0.11 during mid-day trading on Friday, reaching $18.14. 63,934 shares of the company were exchanged, compared to its average volume of 152,129. Athenex has a fifty-two week low of $11.21 and a fifty-two week high of $20.79.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Get a free copy of the Zacks research report on Athenex (ATNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.